<DOC>
	<DOCNO>NCT02900690</DOCNO>
	<brief_summary>The main objective project assess average cost treatment bleed postpartum recombinant activate factor VII ( NovoSeven® ) compare reference strategy . Costs related medicine NovoSeven® generate surplus , also avoids case costly invasive procedure . It interest compare average cost complete strategy support .</brief_summary>
	<brief_title>Health Economics Evaluation Management Severe Postpartum Hemorrhage : Comparison Recombinant Activated Factor VII Strategy Reference Strategy</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<criteria>Severe haemorrhage define follow criterion : blood loss great 1500 ml graduate measured bag / hemodynamically unstable / require transfusion pack red blood cell ( 3 ) ; Sulprostone ( Nalador® ) ineffective ; Age 18 year ; The term 27 SA ( child 's viability ) ; Without anthropomorphic limit ; The outcome pregnancy normal pathological ; Informed consent `` emergency procedure '' sign husband family . minor , major guardianship , personal history venous arterial thrombosis may consindicate treatment rFVIIa refuse sign consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>